Signature HealthCARE Facilities Ranked as America’s Best in Newsweek 2022 Survey
January 25, 2022 13:17 ET
|
Signature Healthcare
Louisville, Ky., Jan. 25, 2022 (GLOBE NEWSWIRE) -- In the ever-changing environment of long-term care during our nation’s on-going pandemic, the balance between enduring and thriving is a daunting...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Everstream Analytics Supply Chain Risk Solutions Now Available on Oracle Cloud Marketplace
January 24, 2022 10:00 ET
|
Everstream Analytics
SAN MARCOS, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Everstream Analytics, a leading provider of Supply Chain Risk Analytics and a member of Oracle PartnerNetwork (OPN), today announced that...
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
January 24, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
Given the Current Testing Restraints, Luxor Scientific Reiterates Excess Capacity for COVID-19 Testing
January 19, 2022 14:02 ET
|
Luxor Scientific, LLC.
GREENVILLE, S.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Luxor Scientific, a full-service clinical testing laboratory that provides laboratory services nationally and for individuals within the region,...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
January 18, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
January 14, 2022 07:30 ET
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Aktuelle Veröffentlichungen verschiedener unabhängiger Labore bestätigen, dass die neutralisierende Wirkung von ADG20 mit anderen Antikörpern vergleichbar ist, die die Aktivität gegen Omikron...
Adagio Therapeutics résume l'activité neutralisante de l'ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Des publications récentes de plusieurs laboratoires indépendants montrent que l'ADG20 a une activité neutralisante présentant une puissance comparable à d'autres anticorps et qui reste active contre...